p.novotny
TL2 Regular · Prague, CZ
Lifter. Interested in preserving what I spent a decade building while losing fat.
Joined 3 June 2025 · last posted 4d
102Posts here
0Topics
1Solutions
138Likes received
213Likes given
18Badges
115Days visited
1.1kPosts read
Stated areas
Recent activity
Full stream-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #106 · Access › International · 24 Jul 2026 · 4 likes Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
-
Restarting after a long gap: what the labelling implies Replied, post #37 · Practice › Dosing & titration · 21 Jul 2026 · 3 likes The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #24 · Sourcing › Regulatory · 15 Jul 2026 · 0 likes Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date…
-
Follow-up: Signs of dehydration worth acting on Replied, post #25 · Safety › Adverse events · 15 Jul 2026 · 0 likes Serious and unexpected events are the ones to document and report. Serious means hospitalization-level serious. Unexpected means not in the drug's known profile. Both…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #60 · Practice › Dosing & titration · 13 Jul 2026 · 8 likes Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #57 · Compounds › Retatrutide · 12 Jul 2026 · 2 likes I read post #55 twice before replying, because I had assumed the opposite. Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist.…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #52 · Analytics › Impurities & related substances · 6 Jul 2026 · 13 likes I read post #50 twice before replying, because I had assumed the opposite. Truncation products: fragments from incomplete synthesis or from degradation. They elute…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #111 · Evidence › Journal club · 5 Jul 2026 · 20 likes Coming back to post #109, because the follow-up matters more than the original answer. SOUL (N Engl J Med 2025): Oral semaglutide cardiovascular outcomes. Extends the…
-
Submitting a sample: the process end to end Replied, post #58 · Sourcing › Independent verification · 4 Jul 2026 · 29 likes This follows post #55 rather than contradicting it. Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a…
-
NHS criteria and how they are applied in practice Replied, post #8 · Regional › UK & Ireland · 21 Jun 2026 · 2 likes post #7 is right about the mechanism and I think understates the practical bit. Compounding pharmacies: UK allows compounding under specific conditions when a licensed…
-
Racemisation and why it is invisible to a mass measurement Replied, post #123 · Analytics › Impurities & related substances · 15 Jun 2026 · 0 likes Deletion sequences (incomplete coupling during synthesis): lower in mass by one residue. Chromatographically they usually elute earlier or later depending on the…
-
Fixed versus detachable needles: the trade-offs — does this still hold? Replied, post #7 · Devices › Syringes & needles · 13 Jun 2026 · 0 likes I read post #5 twice before replying, because I had assumed the opposite. Reading units correctly: look at the marking from the side, not from above or below. The…